OBJECTIVES: Human papillomavirus (HPV), one of the commonest sexually transmitted infections, may be a cofactor in HIV acquisition. We systematically reviewed the evidence for an association of HPV infection with HIV acquisition in women, heterosexual men and men who have sex with men (MSM). DESIGN: : Systematic review and meta-analysis. METHODS: Studies meeting inclusion criteria in Pubmed, Embase and conference abstracts up to 29 July 2011 were identified. Random effects meta-analyses were performed to calculate summary hazard ratios (HR). Publication bias and statistical heterogeneity were evaluated and population attributable fractions (PAFs) calculated. RESULTS: Eight articles were included, with previously unpublished data from five authors. Seven studies found an association between prevalent HPV and HIV acquisition. Risk of HIV acquisition in women doubled with prevalent HPV infection with any genotype [HR = 2.06 (95% CI = 1.44-2.94), I = 0%], although adjustment for confounders was often inadequate. The effect was similar for high-risk [HR = 1.99 (95% CI = 1.54-2.56), I = 8.4%] and low-risk [HR = 2.01 (95% CI = 1.27-3.20), I = 0%] HPV genotypes with weak evidence of publication bias (P = 0.06). Two studies in men were identified: both showed an association between HPV infection and HIV acquisition. Unpublished data from one of two studies in women indicated an association between genotypes targeted by HPV vaccines and HIV acquisition. PAFs for HIV attributable to infection with any HPV genotype ranged between 21 and 37%. CONCLUSION: If further studies validate the association between HPV infection and HIV acquisition, HPV vaccines may reduce HIV incidence in high HPV prevalence populations, in addition to preventing cervical cancer. HIV surveillance studies during implementation of HPV vaccine programmes are warranted.
OBJECTIVES: Human papillomavirus (HPV), one of the commonest sexually transmitted infections, may be a cofactor in HIV acquisition. We systematically reviewed the evidence for an association of HPV infection with HIV acquisition in women, heterosexual men and men who have sex with men (MSM). DESIGN: : Systematic review and meta-analysis. METHODS: Studies meeting inclusion criteria in Pubmed, Embase and conference abstracts up to 29 July 2011 were identified. Random effects meta-analyses were performed to calculate summary hazard ratios (HR). Publication bias and statistical heterogeneity were evaluated and population attributable fractions (PAFs) calculated. RESULTS: Eight articles were included, with previously unpublished data from five authors. Seven studies found an association between prevalent HPV and HIV acquisition. Risk of HIV acquisition in women doubled with prevalent HPV infection with any genotype [HR = 2.06 (95% CI = 1.44-2.94), I = 0%], although adjustment for confounders was often inadequate. The effect was similar for high-risk [HR = 1.99 (95% CI = 1.54-2.56), I = 8.4%] and low-risk [HR = 2.01 (95% CI = 1.27-3.20), I = 0%] HPV genotypes with weak evidence of publication bias (P = 0.06). Two studies in men were identified: both showed an association between HPV infection and HIV acquisition. Unpublished data from one of two studies in women indicated an association between genotypes targeted by HPV vaccines and HIV acquisition. PAFs for HIV attributable to infection with any HPV genotype ranged between 21 and 37%. CONCLUSION: If further studies validate the association between HPV infection and HIV acquisition, HPV vaccines may reduce HIV incidence in high HPV prevalence populations, in addition to preventing cervical cancer. HIV surveillance studies during implementation of HPV vaccine programmes are warranted.
Authors: Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen Journal: Lancet Oncol Date: 2011-11-08 Impact factor: 41.316
Authors: Lot de Witte; Alexey Nabatov; Marjorie Pion; Donna Fluitsma; Marein A W P de Jong; Tanja de Gruijl; Vincent Piguet; Yvette van Kooyk; Teunis B H Geijtenbeek Journal: Nat Med Date: 2007-03-04 Impact factor: 53.440
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: PLoS Med Date: 2009-07-21 Impact factor: 11.069
Authors: Niall Buckley; Ashley Huber; Yungtai Lo; Philip E Castle; Kimdar Kemal; Robert D Burk; Howard D Strickler; Mark H Einstein; Mary Young; Kathryn Anastos; Betsy C Herold Journal: Am J Reprod Immunol Date: 2015-12-18 Impact factor: 3.886
Authors: Mayla Hsu; Meropi Aravantinou; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Nina Derby; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani Journal: AIDS Res Hum Retroviruses Date: 2013-11-22 Impact factor: 2.205
Authors: Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano Journal: J Infect Date: 2015-10-19 Impact factor: 6.072
Authors: Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak Journal: J Korean Med Sci Date: 2013-12-26 Impact factor: 2.153